Workflow
剑桥科技: 股票交易异常波动公告

Core Viewpoint - The announcement from Shanghai Cambridge Technology Co., Ltd. addresses the abnormal fluctuations in its A-share stock price, confirming that there are no undisclosed significant matters affecting the company or its stock price [1][2]. Group 1: Stock Trading Abnormalities - The company's A-share stock experienced a cumulative price deviation of 20% in June 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1]. - The company has verified with its controlling shareholder and actual controller that there are no undisclosed significant matters that could impact the stock price [2]. Group 2: Operational Status - The company's daily operations have not undergone significant changes, and there have been no major adjustments in the market environment or industry policies affecting its production costs and sales [2]. - There are no major asset restructuring, share issuance, or other significant transactions currently planned that could impact the company [2]. Group 3: Market Sentiment and Media Reports - The company conducted a self-examination and found no media reports or market rumors that significantly influenced its stock price [2]. - There are no hot concept matters related to the company that could affect trading prices [2]. Group 4: Other Sensitive Information - As of the announcement date, there are no other significant matters affecting the stock price fluctuations, and no insider trading has occurred among directors, supervisors, or major shareholders during the abnormal trading period [3]. - The company has disclosed a plan for its controlling shareholder to reduce holdings by up to 8,041,254 shares, representing 3.00% of total shares, which is currently in the implementation phase [4]. Group 5: Future Listings and Regulatory Approvals - The company has submitted an application for issuing overseas listed foreign shares (H shares) to the Hong Kong Stock Exchange, which is still subject to approval from various regulatory bodies [5]. - The company will fulfill its information disclosure obligations based on the progress of this matter [5].